SYMPLICITY FLEX: Renal sympathetic denervation in patients with resistant hypertension

Mild refractory hypertension patients were defined as those with daytime systolic BP 135-149 and diastolic BP 90-94 mmHg in ambulatory monitoring. They were randomized to renal denervation (n = 35) versus control invasive procedure (n = 36). The primary end point was the change in systolic pressure of 24 hours ambulatory monitoring at 6 months. Symplicity Flex catheter (Medtronic) was used in the renal ablation group, making 4-6 runs circumferential ablation 2 minutes for each renal artery distal to proximal. The operators had at least 20 procedures experience to qualify for the study. The control group underwent renal artery angiography and sham procedure guided by acoustic signals and saline infusion. At 6 months, results indicated that the mean decrease in systolic blood pressure of 8.3 mmHg (p = 0.042) in the renal ablation group versus control group.

2_steffen_desch
Steffen Desch
2014-09-17

Original title: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension.

More articles by this author

EVERBIO II: Bio-absorbable stent Absorb versus everolimus-eluting or biolimus stents

The new generation drug-eluting everolimus or biolimus stents have proved superior to the first generation. However, neo intimal proliferation and late thrombosis remains a...

EXCITE ISR: Excimer laser versus balloon angioplasty for stent restenosis of the superficial femoral

This multicenter, prospective, randomized trial compared the Excimer laser atherectomy (Excimer Laser Atherectomy = ELA, Spectranetics, Inc.) with a balloon angioplasty in patients with...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...